Invasive Pulmonary Aspergillosis (IPA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Invasive Pulmonary Aspergillosis (IPA) Market Outlook

Thelansis’s “Invasive Pulmonary Aspergillosis (IPA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Invasive Pulmonary Aspergillosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Invasive Pulmonary Aspergillosis (IPA) Overview

Invasive pulmonary aspergillosis (IPA) is a severe fungal infection associated with a high mortality rate. The incidence of IPA is on the rise, primarily due to the increasing number of patients undergoing transplants, receiving chemotherapy, and undergoing immunosuppressive therapy. Invasive pulmonary aspergillosis typically manifests in two distinct scenarios:

1. The classic form of invasive pulmonary aspergillosis occurs as primary pneumonia in patients with profound immunosuppression, such as prolonged neutropenia. This particular presentation has been recognized for many years.
2. Another common scenario is secondary nosocomial pneumonia, which affects patients admitted to the ICU for other reasons, like ARDS caused by influenza. It is a challenging diagnosis because critically ill patients with superinfections of aspergillus are not usually profoundly immunosuppressed. This superinfection can closely resemble bacterial pneumonia or ARDS and may be overshadowed by the patient's other medical issues.

The diagnosis of IPA is complicated due to the non-specific nature of its symptoms. The mainstay of therapy for IPA is Voriconazole. This condition primarily affects severely immunocompromised individuals, including those with prolonged neutropenia resulting from chemotherapy, immunosuppressive therapy, post-hematopoietic stem cell transplant (SCT), or solid organ transplant. When evaluating a child with a cystic or cavitary lung lesion, the list of potential causes is extensive and includes both congenital and acquired lung abnormalities. Congenital cystic lesions include lobar emphysema, cystic adenomatoid malformations, pleuropulmonary blastoma, bronchogenic cysts, and pulmonary sequestration. Acquired lung lesions are categorized as infectious, neoplastic, or stemming from miscellaneous causes. Bacterial and fungal infections predominate among the common infectious causes, while parasitic infestations like paragonimiasis and hydatidosis are rare outside of endemic regions. Pulmonary cysts or pneumatoceles are most commonly associated with organisms such as Staphylococcus, Pseudomonas, Klebsiella, and anaerobes. Lung abscesses can be caused by gram-negative bacteria, anaerobes, and occasionally Staphylococcus.

• The overall one-year mortality rate for IPA is 32%. Specifically, patients with COVID-19 in the ICU have the highest one-year mortality rate, followed by those with acute myeloid leukemia and aplastic anemia, with mortality rates of 54%, 50%, and 39%, respectively.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: